354 related articles for article (PubMed ID: 16132345)
21. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
Tagen M; Zhuang Y; Zhang F; Harstead KE; Shen J; Schaiquevich P; Fraga CH; Panetta JC; Waters CM; Stewart CF
Drug Metab Lett; 2010 Dec; 4(4):195-201. PubMed ID: 20583968
[TBL] [Abstract][Full Text] [Related]
23. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
24. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
Lee HJ; Choi CH
BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
[TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state.
Sauna ZE; Nandigama K; Ambudkar SV
J Biol Chem; 2004 Nov; 279(47):48855-64. PubMed ID: 15364914
[TBL] [Abstract][Full Text] [Related]
26. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
Sawyer TE; Bonner JA
Br J Cancer Suppl; 1996 Jul; 27():S109-13. PubMed ID: 8763860
[TBL] [Abstract][Full Text] [Related]
27. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
28. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
32. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan (CPT-11): a brief overview.
Rivory LP
Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
[TBL] [Abstract][Full Text] [Related]
34. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
35. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
36. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
37. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
[TBL] [Abstract][Full Text] [Related]
38. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
40. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]